Why Furiex Pharmaceuticals (FURX) Stock Soared Today

NEW YORK (TheStreet) -- Furiex Pharmaceuticals  (FURX) surged 28.57% to $103.05 at the close of trading on Monday after Forest Laboratories  (FRX) announced it would acquire the company for $1.5 billion.

This deal comes more than two months after news that Actavis, based in Ireland, would buy Forest for approximately $25 billion in a deal that should close in mid-2014. Forest said Monday that Actavis agreed to and supports the Furiex acquisition, according to USA Today.

Forest said it would pay approximately $1.1 billion in cash, or $95 per share, for Furiex. and would pay an additional amount of up to approximately $360 million depending on the development of eluxadoline. The drug treats symptoms of diarrhea-predominant irritable bowel syndrome, which affects nearly 28 million people in the U.S. and Europe.

Several law firms subsequently announced investigations into the deal.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

FURX Chart

FURX data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Insider Trading Alert - FURX, EGP And FLT Traded By Insiders

U.S. Stocks Mount Midday Turnaround to Close Higher, Bank of America Plunges

Forest Laboratories Inks $1.4B Deal for Furiex

Is Merger Monday Back? 3 Big Deals Say Yes: StockTwits